enow.com Web Search

  1. Ad

    related to: pseudobulbar affect medication fda approved

Search results

  1. Results from the WOW.Com Content Network
  2. Pseudobulbar affect - Wikipedia

    en.wikipedia.org/wiki/Pseudobulbar_affect

    Pseudobulbar affect; Other names: Emotional incontinence: Specialty: ... and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010.

  3. Pseudobulbar palsy - Wikipedia

    en.wikipedia.org/wiki/Pseudobulbar_palsy

    Nuedexta is an FDA approved medication for pseudobulbar affect. Dextromethorphan, an N-methyl-D-aspartate receptor antagonist, inhibits glutamatergic transmission in the regions of the brainstem and cerebellum, which are hypothesized to be involved in pseudobulbar symptoms, and acts as a sigma ligand, binding to the sigma-1 receptors that ...

  4. Dextromethorphan - Wikipedia

    en.wikipedia.org/wiki/Dextromethorphan

    In 2010, the FDA approved the combination drug dextromethorphan/quinidine under the brand name Nuedexta [19] for the treatment of pseudobulbar affect (uncontrollable laughing/crying). Dextromethorphan is the active therapeutic agent in the combination; quinidine merely serves to inhibit the enzymatic degradation of dextromethorphan and thereby ...

  5. Newly approved medication for postpartum depression has ties ...

    www.aol.com/newly-approved-medication-postpartum...

    This is the first pill targeted at depression that occurs shortly after childbirth.

  6. FDA approves opioid-free pain medication with 'no sign of ...

    www.aol.com/fda-approves-opioid-free-pain...

    A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

  7. Dextromethorphan/quinidine - Wikipedia

    en.wikipedia.org/wiki/Dextromethorphan/quinidine

    Concomitant use with drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., thioridazine, pimozide); effects on QT interval may be increased Concomitant use with MAOIs or use of MAOIs within 14 days; risk of serious, potentially fatal, drug interactions including serotonin syndrome

  8. FDA approves new pain medication as an alternative to ... - AOL

    www.aol.com/fda-approves-pain-medication...

    The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

  9. Management of multiple sclerosis - Wikipedia

    en.wikipedia.org/wiki/Management_of_multiple...

    [135] [138] [139] For those patients with MS who have pseudobulbar affect (PBA), characterized by uncontrollable episodes of crying and/or laughing, or other emotional displays, Dextromethorphan/quinidine can be considered as treatment as it is the only FDA approved drug for treatment for PBA, though other medications such as selective ...

  1. Ad

    related to: pseudobulbar affect medication fda approved